Effects of U0126 on growth and activation of mitogen-activated protein kinases in Aspergillus fumigatus.
- Author:
Dong-Mei MA
1
;
Ya-Juan JI
;
Fang YANG
;
Wei LIU
;
Zhe WAN
;
Ruo-Yu LI
Author Information
- Publication Type:Journal Article
- MeSH: Aspergillus fumigatus; drug effects; enzymology; growth & development; Butadienes; pharmacology; Enzyme Activation; drug effects; Enzyme Inhibitors; pharmacology; MAP Kinase Signaling System; drug effects; Mitogen-Activated Protein Kinases; metabolism; Nitriles; pharmacology
- From: Chinese Medical Journal 2013;126(2):220-225
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDInvasive aspergillosis (IA), which is mainly caused by Aspergillus fumigatus (A. fumigatus), is a major cause of morbidity and mortality in immunocompromised patients. Despite considerable progress in currently available antifungals the mortality still remains high in critically ill patients. U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells. The purpose of this study was to explore the role of U0126 on growth inhibition and activation of mitogen-activated protein kinases (MAPKs) in A. fumigatus.
METHODSGermination percentage and hyphae growth in A. fumigatus treated with U0126 were observed and compared with untreated controls. Western blotting analysis was used to detect changes in activation of SakA, MpkA and MpkB.
RESULTSU0126 inhibited germination and hyphae growth in A. fumigatus and enhanced the phosphorylation of SakA and MpkA under oxidative stress. U0126 at 10 µmol/L did not block the activation of MpkB during nitrogen starvation stress.
CONCLUSIONU0126 shows promise as an antifungal candidate and the MAPK pathway may be a possible antifungal drug target for A. fumigatus.
